When we compared distribution of genotypes by participants’ characteristics (ER, tumor stage and BMI), carriers of the GSTM1 null mutation were more likely to have stage 3 tumors (χ2=3.87 P=0.05) compared to non-carriers (Table 2). The gene discussed is GSTM1; the disease is neoplasm.